Dementia linked to diabetes, herpes as research looks beyond brain proteins to find cause
Protein clumps in the brain have long been associated with Alzheimer's, but other potential causes of the condition are now ...
ALZFORUM1d
Plaque Removal Delays Onset of Familial Alzheimer’s Disease
The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...
Medscape2d
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
European Medical Journal2d
Neuroimaging Reveals Donanemab Treatment Increases ARIA Risk in Alzheimer’s Disease
DONANEMAB TREATMENT significantly increases the risk of amyloid-related imaging abnormalities (ARIA) in early symptomatic ...
Medscape2d
Neurovascular Clues Offer New Path to Early Alzheimer’s
A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...
Scientific American2d
Safe, Cheap and Non-Invasive: Ultrasound Could Treat Cancer, Psychiatric Disorders and More
A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...
Healio3d
FDA recap: First new treatment for stroke in 3 decades, generic rivaroxaban and more
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Precision Medicine Online3d
New Treatments Spur Interest in Broader Genetic Screening for Rare Heart Condition
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
University of California, San Francisco4d
How Your Brain Manages Cholesterol Could Increase Alzheimer’s Risk
Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.
Rolling Out4d
Promising drug cuts Alzheimer’s risk by half in rare cases
Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Breakthrough Drug Cuts Alzheimer’s Risk by 50% in High-Risk Patients
A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...